Published in J Gastrointestin Liver Dis on June 01, 2008
Lactose malabsorption and intolerance: pathogenesis, diagnosis and treatment. United European Gastroenterol J (2013) 0.85
Lactose malabsorption testing in daily clinical practice: a critical retrospective analysis and comparison of the hydrogen/methane breath test and genetic test (c/t-13910 polymorphism) results. Gastroenterol Res Pract (2014) 0.82
Four-sample lactose hydrogen breath test for diagnosis of lactose malabsorption in irritable bowel syndrome patients with diarrhea. World J Gastroenterol (2015) 0.78
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Res (2016) 0.77
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 4.88
The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet (2003) 3.96
Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology (2002) 3.96
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature (2012) 3.67
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93
Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis (2002) 2.76
A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet (2007) 2.75
Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol (2005) 2.66
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2004) 2.45
Interferon-lambda serum levels in hepatitis C. J Hepatol (2010) 2.28
p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut (2009) 2.20
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
Atypical Ormond's disease associated with bile duct stricture mimicking cholangiocarcinoma. Scand J Gastroenterol (2009) 2.17
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology (2008) 1.82
MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant (2005) 1.82
beta-Trace protein is an alternative marker for glomerular filtration rate in renal transplantation patients. Clin Chem (2005) 1.71
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol (2013) 1.70
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Characteristics of oesophageal bolus transport in patients with mild oesophagitis. Eur J Gastroenterol Hepatol (2005) 1.64
Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem (2007) 1.62
Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int (2008) 1.62
Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure. J Hepatol (2002) 1.60
Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology (2012) 1.60
Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem (2006) 1.60
Pseudomembranous and obstructive Aspergillus tracheobronchitis - optimal diagnostic strategy and outcome. Mycoses (2006) 1.58
Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol (2013) 1.57
Biliary cast syndrome in sclerosing cholangitis. Dig Liver Dis (2010) 1.55
Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-alpha. Crit Care Med (2004) 1.55
Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology (2005) 1.55
Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus. Hepatology (2013) 1.53
Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays. J Immunol Methods (2005) 1.51
The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol (2005) 1.48
Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion (2003) 1.48
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone disease. Hepatology (2012) 1.47
Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS (2003) 1.47
Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver Int (2008) 1.46
Pitfalls in the diagnosis of intestinal tuberculosis: a case report. Scand J Gastroenterol (2005) 1.46
Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol (2003) 1.46
Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology (2007) 1.46
Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol (2005) 1.42
Esomeprazole-induced central fever with severe myalgia. Ann Pharmacother (2005) 1.41
Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology (2005) 1.35
Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol (2010) 1.35
Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol (2012) 1.34
Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc (2003) 1.27
Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol (2006) 1.26
The genetics of complex cholestatic disorders. Gastroenterology (2013) 1.24
Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology (2004) 1.24
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol (2012) 1.23
Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology (2002) 1.21
The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology (2009) 1.21
Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology (2010) 1.20
Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol (2010) 1.18
Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr (2006) 1.17
HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir Ther (2005) 1.16
Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology (2008) 1.16
Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology (2007) 1.15
Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology (2002) 1.15
Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J Biol Chem (2003) 1.15
siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol (2008) 1.14
The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One (2011) 1.13
Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology (2006) 1.13
New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation. Biochim Biophys Acta (2009) 1.13
Gc-globulin: roles in response to injury. Clin Chem (2006) 1.12
Interacting QTLs for cholesterol gallstones and gallbladder mucin in AKR and SWR strains of mice. Physiol Genomics (2002) 1.11
Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun (2004) 1.11
Early up-regulation of chemokine expression in fulminant hepatic failure. J Pathol (2003) 1.11
Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and outcome of intensive care. J Crit Care (2009) 1.11
Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)--core protein is mediated by toll like receptors (TLRs) 2 and 4. Immunol Lett (2002) 1.11
HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. World J Gastroenterol (2002) 1.11
Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol (2005) 1.10
Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease. J Hepatol (2010) 1.10
Significant factors associated with fatal outcome in emergency open surgery for perforated peptic ulcer. World J Gastroenterol (2003) 1.09
Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol (2007) 1.08
Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int (2006) 1.07
Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol (2005) 1.07
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med (2012) 1.07
NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab Invest (2012) 1.06
The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol (2007) 1.06
IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling. Am J Physiol Gastrointest Liver Physiol (2012) 1.06
Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology (2003) 1.06
Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin. Biochim Biophys Acta (2007) 1.05
Cholecystitis in neutropenic patients: retrospective study and systematic review. Leuk Res (2006) 1.04
Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther (2003) 1.04
FOXO transcription factors regulate innate immune mechanisms in respiratory epithelial cells. J Immunol (2013) 1.03
Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology (2008) 1.03
Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol (2005) 1.03